SCHEMBL25519675

SCHEMBL25519675

Cc1ccc(C)c(S(=O)(=O)C2CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
RAB9A P51151 1/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
F2 P00734 1/20 0.40
MAPT P10636 1/20 0.40
XBP1 P17861 1/20 0.40
EDNRB P24530 1/20 0.39
EDNRA P25101 1/20 0.39
UBE2N P61088 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25519971 0.84 ALDH1A1 (0.43) ALDH1A1TSHRGAALMNASMN1; SMN2
SCHEMBL25519678 0.81 L3MBTL1 (0.39) ALDH1A1TSHRGAASMN1; SMN2L3MBTL1
SCHEMBL25519699 0.81 SMN1; SMN2 (0.42) ALDH1A1TSHRGAASMN1; SMN2L3MBTL1
SCHEMBL25795157 0.78 MCL1 (0.42) ALDH1A1TSHRLMNASMN1; SMN2L3MBTL1
SCHEMBL1341155 0.75 SMN1; SMN2 (0.41) ALDH1A1TSHRGAASMN1; SMN2L3MBTL1
SCHEMBL7112755 0.74 UBE2N (0.57) ALDH1A1TSHRGAALMNASMN1; SMN2
SCHEMBL29451317 0.74 L3MBTL1 (0.42) ALDH1A1TSHRL3MBTL1TDP1RAB9A
SCHEMBL15040608 0.73 L3MBTL1 (0.68) ALDH1A1TSHRGAASMN1; SMN2L3MBTL1
SCHEMBL16712195 0.73 ALDH1A1 (0.49) ALDH1A1TSHRGAALMNASMN1; SMN2
SCHEMBL801935 0.73 ALDH1A1 (0.49) ALDH1A1TSHRGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND RAD51, FANCI, BLM ALDH1A1 2893/4885TSHR 3887/4885GAA 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.